Current partner codePEPTIDESDE
NCT06003465·Phase 1·INTERVENTIONAL

A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices

Status

Completed

Phase

Phase 1

Enrollment

57

Locations

3

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The main purpose of this study is to look at the amount of the study drug, LY3437943, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of LY3437943 and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 16 weeks, including screening.

Interventions

Treatment arms and agents.

DRUG

LY3437943

Administered SC

DEVICE

Test

Used to administer LY3437943 SC

DEVICE

Reference

Used to administer LY3437943 SC

Timeline

From registration to results.

  1. First posted

    Aug 22, 2023

  2. Study start

    Aug 29, 2023

  3. Primary completion

    Feb 8, 2024

  4. Study completion

    Feb 8, 2024

  5. Results posted

    Not reported

  6. Registry updated

    Mar 29, 2024

Outcomes

What the study measures.

Primary outcomes

Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943

Time frame · Predose up to 43 days postdose

PK: Cmax of LY3437943

PK: Area Under the Plasma Concentration Versus Time Curve from Zero to T, Last Time Point (AUC[0-tlast]) of LY3437943

Time frame · Predose up to 43 days postdose

PK: AUC\[0-tlast\] of LY3437943

PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943

Time frame · Predose up to 43 days postdose

PK: AUC(0-∞) of LY3437943

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
70 Years
Sex
ALL
Healthy volunteers
Yes

Inclusion Criteria: * Healthy males or non-pregnant females as determined by medical history, physical examination, and other screening procedures * Body mass index (BMI) between 18.5 and 32.0 kilograms per meter squared (kg/m²), inclusive * Have clinical laboratory test results, blood pressure and pulse rate that are acceptable for the study * Are agreeable to receiving study treatment by injections under the skin * Males who agree to use highly effective/effective methods of contraception and women not of childbearing potential (postmenopausal or oophorectomized) Exclusion Criteria: * Have or used to have health problems that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study * Smoke more than the equivalent of 10 cigarettes per day * Is a known user of drugs of abuse * Have known allergies to LY3437943 or related compounds

Study locations

3 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

Qps-Mra, Llc

Miami, Florida, United States

ICON Early Phase Services

San Antonio, Texas, United States

ICON

Salt Lake City, Utah, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Retatrutide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.